Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
Rattachement africain : us, il. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response. METHODS: Patients with systemic lupus erythematosus (SLE) (n = 268) undergoing clinically indicated kidney biopsies (urine protein/creatinine ratio [UPCR] ≥ 0.5) were recruited through the AMP Rheumatoid Arthritis and SLE Network. Serum was collected at biopsy and 3-, 6-, and 12-month postbiopsy, alongside samples from 22 healthy controls. Concentrations of 66 immune mediators were quantified using xMAP multiplex assays, and (TACE) measured by enzyme-linked immunosorbent assay. Seven mediators with >95% values below detection limits were excluded from analyses. Bootstrapped least absolute shrinkage and selection operator (LASSO) regression identified proliferative LN (class III/IV ± V) predictors from baseline mediators. Associations with 12-month treatment response (complete/partial vs no response) were tested using three-month changes in LASSO-selected mediators and UPCR via logistic regression. Molecular clustering of mediator profiles was performed to identify LN subgroups. RESULTS: Proliferative patients with LN (class [III or IV] ± V; n = 160) displayed a distinct mediator profile compared with nonproliferative LN (class I, II, or V; n = 96). LASSO regression identified 20 mediators predictive of proliferative LN (areas under the curve, 0.82; 95% confidence interval [CI], 0.81-0.91), including elevated syndecan-1, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II, and vascular cell adhesion molecule 1 (VCAM-1), as well as decreased CCL3//macrophage inflammatory protein 1α, CD40 ligand, and interleukin-5 levels. Among proliferative patients with LN, 3-month reductions in syndecan-1 and VCAM-1, mediators associated with intrarenal LN activity and/or chronicity, predicted the 12-month treatment response. A model incorporated these reductions and a decline in UPCR-predicted treatment response in proliferative LN (0.90; 95% CI, 0.82-0.98). Molecular clustering revealed four distinct LN subgroups with unique soluble mediator signatures and clinical features not captured by histology alone. CONCLUSION: Serum soluble mediators, particularly syndecan-1 and VCAM-1, reflect LN histologic activity, and early decreases predict treatment response, supporting their potential use as noninvasive longitudinal biomarkers. The substantial heterogeneity within LN highlights the potential for biomarker-guided reclassification to advance precision medicine approaches.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment
- Date Crossref
- 03/12/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
Oklahoma Medical Research Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
New York University pays non établi dans la noticeUniversité ou école supérieure
-
Feinstein Institute for Medical Research pays non établi dans la noticeStructure de recherche
-
Stanford University pays non établi dans la noticeUniversité ou école supérieure
-
Cedars-Sinai Medical Center pays non établi dans la noticeÉtablissement de santé
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
University of California San Diego pays non établi dans la noticeUniversité ou école supérieure
-
Albert Einstein College of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Bar-Ilan University pays non établi dans la noticeUniversité ou école supérieure
-
Zefat Academic College pays non établi dans la noticeUniversité ou école supérieure
-
University of Rochester Medicine pays non établi dans la noticeÉtablissement de santé
Johns Hopkins University, Oklahoma Medical Research Foundation et New York University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.